Electrophysiology Leads segmentation by application isolates demand across three principal therapeutic uses: pacing, defibrillation, and cardiac resynchronization therapy (CRT). The pacing application, accounting for roughly 45 % of total shipments, underpins the majority of single‑chamber and dual‑chamber pacemaker implants, where lead reliability directly influences device longevity and patient morbidity. Defibrillation leads, representing about 30 % of the market, are integral to ICD systems that deliver high‑energy shocks to terminate ventricular arrhythmias; their design emphasizes high‑voltage insulation and rapid discharge capability, which commands higher unit prices and drives a distinct cost structure. CRT leads, comprising the remaining 25 %, combine ventricular and atrial electrodes to synchronize myocardial contraction in heart‑failure patients, a niche that has expanded following guideline endorsements and reimbursement reforms. These application‑specific shares not only reflect clinical prevalence but also shape manufacturing focus, R&D investment, and supply‑chain allocation within the overall Electrophysiology Leads market. The distribution illustrates how therapeutic priorities translate into quantifiable market taxonomy.